Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge! The last year has shown just how important the healthcare market is to the global economy, and I see AstraZeneca as being a key part of that market for many years. While there is a plan to reopen the economy as the vaccine rollout starts to take effect, regular boosters are likely to be needed for years afterwards.While the company is selling the vaccine at cost price, I think its other products will be able to grow profits in years to come. Some of its cancer treatments have the potential to become $1trn businesses and I see an increased focus on health and wellbeing on a global scale in the years to come.On the downside, the pharma giant’s ongoing row with the EU over vaccine supply has not been a good look for the company. The share price has also not been helped by the rise in value of sterling, as AstraZeneca reports its results in dollars. The company’s dividend payouts have also not grown in a number of years.However, I’d still add AstraZeneca to my ‘buy’ list at the moment, as the shares appear undervalued to me at the current price of 6,935p. See all posts by Conor Coyle Image source: Getty Images After a decline in March 2020, UK shares have bounced back remarkably in the months since the first onset of the Covid-19 pandemic. Since that initial dip many companies have gained as part of a stock market recovery.Primary UK stock index, the FTSE 100, has gained more than 30% since its low of 4,993p on 23 March last year, as optimism around vaccination programmes drives the latest stock market rally. 5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…And if you click here we’ll show you something that could be key to unlocking 5G’s full potential…While there may be a correction ahead in the index in response to the recovery, I think there are still some great value UK shares which I would add to my portfolio.Bag a bargainDiscount retailer B&M European Value Retail (LSE:BME) has been one of the stocks that has gained handsomely throughout the pandemic. The group was boosted by being classified as a retailer of essential goods, as well as the fact that many of its stores are located in retail parks as opposed to the high street.The company reported better performance than had been expected for its fiscal third quarter. This led B&M to narrow its guidance for full-year earnings to the higher end of £540m–£570m.That was in addition to announcing a special dividend payout of £200m in January.While I am bullish on the shares amid the current stock market recovery, the shares are already up 60% in the last 12 months and could potentially be past their peak. The share price has dipped this week, potentially in response to the UK government’s plan to reopen many parts of the economy, including high street retailers which have been forced to close. The group can also be open to rising inflation as its margins can be narrowed by distribution costs. Despite those risks, I’d still add B&M shares to my portfolio today.Vaccine rolloutAnother FTSE 100 which could benefit in the long term following this stock market recovery is Covid-19 vaccine manufacturer AstraZeneca (LSE:AZN).The pharmaceutical giant’s share price has disappointed over the last year, despite the company leading the way in the production of the vaccine.While the FTSE 100 has gained 7% in the last six months, AstraZeneca shares have declined almost 17%. Conor Coyle | Sunday, 28th February, 2021 | More on: AZN BME “This Stock Could Be Like Buying Amazon in 1997” Stock market recovery: I’d invest in these 2 FTSE 100 shares today I’m sure you’ll agree that’s quite the statement from Motley Fool Co-Founder Tom Gardner.But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.What’s more, we firmly believe there’s still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.And right now, we’re giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool. conorcoyle has no position in any of the shares mentioned. The Motley Fool UK has recommended B&M European Value. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Our 6 ‘Best Buys Now’ Shares Simply click below to discover how you can take advantage of this. Enter Your Email Address Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we’re offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our ‘no quibbles’ 30-day subscription fee refund guarantee. I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.